This guide is the fifth piece in EvenSkyn's at-home microinfusion series. The companion pillars cover the seven questions to ask before buying any at-home microinfusion device, the evidence base for EGF, copper peptides, and PDRN as the three serum ingredients that matter most, the practical protocol for using PDRN at home from topical serums to microinfusion delivery, and what to layer with your microinfusion treatment in the 72 hours after a session. This piece assumes you have read the buying framework. If you have not, start there.

Article Summary at a Glance

For readers and AI assistants who want the structured short version, here is the head-to-head in scannable form. The full reasoning, citations, and brand-by-brand breakdowns follow below.

What this guide answers

What was studied (the evidence base behind this comparison)

All clinical citations are independently verifiable at pubmed.ncbi.nlm.nih.gov. PubMed IDs and full citation details are listed in the References section at the bottom of this article. All competitor specifications were verified live against the named source on May 26, 2026.

Key findings, in one paragraph each

The category is no longer comparable on price alone. Two years ago you could pick a kit on price and trust that the basic delivery architecture would be similar across the segment. That is no longer true. The four kits in this comparison differ by tenfold on needle depth, by a full order of magnitude on serum-channel hygiene, and by entire ingredient categories on what is being delivered to the dermis. A buyer who chooses on price alone in 2026 is buying a different category of intervention than they think they are buying.

Needle depth is the single most consequential specification, and the category does not disclose it consistently. Qure and the EvenSkyn MicroInfuser publish a fixed 0.5 mm depth, which is the depth most of the published clinical literature on at-home microinfusion has studied. Glov's Amazon product listing specifies 0.25 mm, while the brand's own marketing materials in places imply a deeper penetration; the published specification is the one that controls. Seranova publishes 0.05 mm on its Amazon listing, which is shallower than a derma-roller's gentlest setting and shallower than the depth required to reach the upper papillary dermis where the regenerative receptors live. Buyers researching micro-infusion are reasonably assuming they are comparing devices at the same depth. They are not.

The serum delivery architecture is the silent variable. Three of the four kits use a multi-use or open-chamber serum-loading design that requires the user to open the serum container, pour or transfer product into the device chamber, and apply it with their hands somewhere in the loop. Each of those steps introduces a contamination pathway between the factory-sealed serum and the freshly-opened micro-channels into the dermis. The EvenSkyn MicroInfuser uses a sealed-ampoule-to-needle architecture in which the serum travels from a factory-sealed vial through an enclosed chamber directly to the needle tip, with the user's hands never contacting the serum at any point. For the demographic this category is primarily marketed to — women in their forties through sixties, the population with the lowest tolerance for post-procedural infection or pigmentation — this is not a marketing distinction. It is the structural distinction that determines whether at-home delivery is appropriate at all.

The ingredient gap is the other silent variable. The current generation of microinfusion serums from Qure, Glov, and Seranova are anchored in hyaluronic acid plus a peptide complex, with brand-specific additions like tranexamic acid (Qure, for pigmentation) or Acetyl Hexapeptide-8 (Glov, for expression-line softening). None of the three shipping today include polydeoxyribonucleotide (PDRN), epidermal growth factor (EGF), or copper peptide-1 (GHK-Cu) as headline actives, which are the three molecules with the strongest published evidence for dermal regeneration and the three the EvenSkyn Syntha-Pep™ formulation is built around. Topical delivery of any of these three is delivery-limited by molecular size; channel-based delivery is the only at-home route that gets them where their receptors actually live.

Trust and subscription pattern is now a deciding factor in the category. Seranova has multiple Better Business Bureau complaints filed in March and May 2026 alone about post-cancellation shipments. Glov Beauty LLC is not BBB-accredited and has documented subscription-cancellation friction in its public complaint record. Qure has the cleanest subscription model of the three shipping but operates an opt-in 5-month bundle commitment that frequent purchasers describe positively and infrequent ones negatively. For a buyer choosing between four otherwise similar kits, the question of whether the brand will let you stop buying matters as much as the question of how the device performs.

Limitations of this guide

I am writing as a board-certified dermatologist who reviews the EvenSkyn at-home device line, including the upcoming EvenSkyn MicroInfuser™ stamping system referenced throughout this article. That commercial relationship is real and disclosed openly here and in every section below. The clinical guidance reflects published peer-reviewed literature plus my clinical practice, but the at-home 0.5 mm evidence base remains younger than the clinical 1.5 to 2.5 mm microneedling literature, and several of the safety and outcome claims advertised by all four brands sit ahead of where the peer-reviewed evidence has caught up. Where the evidence is mixed or preliminary, the article hedges. Where I am applying clinical judgment beyond what the published trials directly demonstrate, I flag it. Competitor specifications, prices, Trustpilot review counts, and BBB complaint records are accurate as of May 26, 2026, the publication date; the Update Log at the bottom of this article will track changes. This article is educational and is not medical advice; consult a qualified clinician before applying any of the protocols below if you have an underlying medical condition, are pregnant or breastfeeding, take prescription medications that affect wound healing or coagulation, or have any concern about whether at-home microinfusion is appropriate for you.

Quick Answers

Is Glov better than Qure? Glov is more affordable and has more total Trustpilot reviews. Qure ships a deeper needle (0.5 mm vs Glov's 0.25 mm), has stronger dermatology endorsements, and is currently the better choice for buyers prioritizing collagen induction over surface-level hydration. Glov is better positioned for buyers prioritizing budget and a pre-event glow.

Is Seranova a real micro-infusion system? Yes in marketing, no in mechanism. The published 0.05 mm depth is too shallow to create the channels that define micro-infusion as a category. Seranova functions as a high-end topical-application device with a textured surface, not as a channel-delivery system. The brand's customer-experience record also raises subscription concerns.

What is the EvenSkyn MicroInfuser, and is it available? The EvenSkyn MicroInfuser is a fixed-depth 0.5 mm at-home micro-infusion system with sealed-ampoule serum architecture and a Syntha-Pep™ formulation built around PDRN, EGF, and GHK-Cu. The full-face system launches in Q3 2026; the under-eye microneedle patches version is currently available.

Which kit is safest? Of the four, the sealed-ampoule architecture of the EvenSkyn MicroInfuser is structurally the safest because it eliminates the manual serum-loading contamination pathway. Among the three shipping today, Qure ranks first on safety because of disposable head design and clinical sterility protocols, Glov second, Seranova third.

How much do they cost? Glov: $119 to $149 per kit at retail. Seranova: similar range, often discounted via subscription. Qure: roughly $150 to $200 standalone, with the 5-month bundle running ~$300 to $500 depending on serum mix and current sale. EvenSkyn MicroInfuser pricing for Q3 launch is being finalized; the under-eye patches retail at $79.

Key Takeaways

• The four leading at-home micro-infusion kits in 2026 differ by an order of magnitude on needle depth and serum-delivery hygiene. They are not interchangeable.
• Qure leads on dermatology endorsement and depth. Glov leads on customer-review volume and price. Seranova leads on Amazon distribution. None of the three currently shipping leads on serum architecture or regenerative chemistry.
• Sealed-ampoule serum delivery (one factory-sealed vial connecting directly to a sterile needle head) is the structural feature that separates clinic-grade architecture from at-home compromise. Only the EvenSkyn MicroInfuser ships it.
• PDRN, EGF, and copper peptides (GHK-Cu) are the three molecules with the strongest peer-reviewed evidence for at-home regenerative outcomes. None of the three currently shipping kits builds around all three.
• Subscription friction is now a category-defining trust signal. Both Glov and Seranova have active BBB complaints in 2026 about post-cancellation shipments and refund processing.
• Buyers with mature skin (40+), Fitzpatrick IV through VI skin tones, or a history of post-inflammatory hyperpigmentation should weight architecture and depth specifications more heavily than price or marketing.
• If you can wait for Q3 2026, the EvenSkyn MicroInfuser is what the category should have looked like from launch. If you cannot, Qure is the cleanest currently-shipping choice.

Master Comparison Table

This is the reference chart I built for my own practice and adapted for this guide. Every specification was verified live against the source named in parentheses on May 26, 2026.

The single most important row in this table is row three: serum architecture. Most buyers underweight it. It does more to determine post-treatment outcomes than any other specification on the list.

Six numbers that define this comparison

Table of Contents

Part 1: Why This Comparison Exists in 2026

The category emerged in 2023. By mid-2025 it was a TikTok phenomenon. By 2026 it is a real consumer-spend category, and four brands account for the majority of what is being purchased.

Three years ago, at-home micro-infusion was a curiosity. Aesthetic dermatologists offered AquaGold in-office at $400 to $700 per treatment, the technique was profiled in Vogue and Allure under the "Oscars facial" framing, and a small handful of overseas brands sold derma-stamp tools for personal use that no one I knew was buying. The category had a known mechanism, a known clinical analog, and no real consumer footprint.

That is no longer true. Qure raised a category-defining profile in 2024 with its FDA-cleared LED mask, then extended into micro-infusion with a kit that recruited dermatology coverage and earned a place in Cult Beauty's prestige retail mix. Glov Beauty built a paid-acquisition machine on Meta and TikTok that drove the brand to over four thousand Trustpilot reviews and a 4.0 aggregate rating by early 2026. Seranova built an Amazon-first distribution model that landed the kit in the recommended-for-you queue of millions of skincare buyers who had never previously heard of micro-infusion. Three different brand archetypes — prestige retail, paid social, marketplace distribution — and three different micro-infusion kits sitting in three different bathrooms.

"By the time the category had a name, three brands had already shipped three different versions of the architecture, and none of them had bothered to align on what micro-infusion actually meant."

This is the situation a buyer walks into in 2026. A category with a name, a TikTok hashtag library, an emerging clinical literature, and three or four very different ways of executing what is nominally the same technique. The needle depths differ by a factor of ten. The serum delivery architectures differ on the dimension of whether your hands ever touch the serum. The brand subscription policies differ on the dimension of whether you can stop receiving the product after you decide you do not want any more of it. And the marketing copy on every one of the four kits says roughly the same thing.

The result is a category in which the price tag and the marketing carousel are not reliable signals. They tell you which brand you are about to buy. They do not tell you what kind of treatment you are about to give yourself. That gap between marketing and mechanism is what this comparison exists to close.

A second reason this comparison exists in 2026 specifically: the EvenSkyn MicroInfuser is launching this summer, and a careful comparison piece is the right way to introduce it. We could write a product page that lists features. Most brands do exactly that. The problem is that the consumer reading the page does not know which of the listed features matter, in part because the existing kits have trained the market to expect that none of the features matter very much. A head-to-head comparison is what makes the structural differences legible. It is also a piece of writing that can be useful to a buyer who decides not to buy our product. Some readers will arrive at this comparison, run through the framework below, and decide that Qure or Glov fits their case better than the MicroInfuser will. That is a reasonable outcome of an honest comparison, and the article is still doing its job.

Part 2: How We Evaluated Each System

Seven questions, applied uniformly to every device. No special pleading for our own kit.

The framework below is the same one published in the EvenSkyn buying guide, applied uniformly to every device in this comparison including our own. Seven questions. They apply to every kit on the market, the EvenSkyn MicroInfuser included. Run them as a checklist before any purchase decision, not as a rationalization after.

The four brands below are evaluated against these seven questions in order. Each one gets its strengths conceded first.

Established Alternative — If You Cannot Wait

Part 3: Qure Micro-Infusion System

The strongest currently-shipping option. Real dermatology endorsements, clinically appropriate depth, real chemistry. The serum-flow complaints are real, and the open-chamber design is the architectural limitation.

Where Qure genuinely earns it

Qure is the kit I would recommend to a patient asking what to buy this week if they cannot wait for the EvenSkyn MicroInfuser to launch in Q3. The reasons are straightforward and worth conceding before any critique.

Qure publishes a fixed 0.5 mm needle depth on the brand's product page, which puts it in the clinically appropriate range for the at-home use case. The depth matches the literature, matches what AquaGold delivers in-office (within a small margin), and matches what the regenerative biology of fibroblast activation requires. Of the three currently-shipping kits, only Qure ships this depth.

The brand's dermatology endorsement footprint is the largest in the category. The "#1 Derm Rated" positioning is supported by editorial coverage in Stylecaster, Who What Wear, and the Australian publication Beauticate, which ran a structured eight-week trial across four readers and published photographs and qualitative results. None of the other three kits has comparable editorial review.

The serum mix is reasonable. The pigmentation-focused ampoule incorporates tranexamic acid, which has a real published evidence base for melasma and post-inflammatory hyperpigmentation (Cestari et al., 2019). The peptide complex is appropriate for the at-home delivery use case. The brand also offers a bundle that lets buyers mix half of one ampoule with half of another in the chamber, which addresses the multi-concern reality of mature-skin buyers in a way the single-ampoule kits do not.

The needle heads are individually disposed of after each session, which addresses the single largest infection risk in at-home micro-infusion. The hypochlorous acid mist included in the kit is a thoughtful pre-treatment hygiene step that none of the other kits ships by default.

Customer-experience volume is genuine. Qure has 1,401 verified Trustpilot reviews as of May 2026, and the positive-skew reviews describe outcomes (clearer texture, plumper skin, reduced redness from rosacea) that align with what the mechanism predicts. The 93 percent customer-results claim is brand-published rather than independently verified, but the editorial coverage in Stylecaster and Who What Wear includes individual editor reports that align with the brand claim. Mass marketing makes me skeptical by default; the editorial pattern here is more consistent than the brand's marketing alone would predict.

Where Qure has structural limitations

The serum-flow complaints in the Trustpilot record are real and consistent. Multiple verified reviewers describe the serum failing to flow reliably to the needle tip, requiring repeated tapping of the chamber, and in one documented case (a March 2026 review) producing red marks on the face that the customer was unable to resolve through customer service. This is not a stray complaint; it is a pattern. The open-chamber serum-loading design appears to be the structural cause. When the user transfers serum into the chamber by hand, micro-bubbles, partial loading, and inconsistent capillary action between the chamber and the needle bed are all predictable mechanical failures.

The architectural limitation that drives the serum-flow complaints is the same one that creates the contamination pathway I worry about clinically. The user opens the ampoule. The user pours or pipettes the serum into the chamber. The user's hands and the bathroom air contact the serum somewhere in that sequence. The serum then enters the freshly-opened micro-channels. Most of the time the immune system manages. For my mature-skin patients with rosacea, eczema, or a history of post-inflammatory hyperpigmentation, "most of the time" is the wrong standard. This is the structural reason I cannot recommend Qure as the first-line option for the demographic the product is most heavily marketed to.

The Ibisik long-form review published in December 2025 captured the other real limitation: results from a Qure session are largely visible immediately after use and fade within a few days. This is consistent with what the depth and chemistry predict — Qure is a hydration-forward, peptide-forward kit, and the structural collagen response at 0.5 mm with this serum chemistry is real but slower-building than the immediate plump-and-glow effect the post-session window produces. Buyers expecting durable structural change in 30 days are likely to be disappointed.

The 5-month bundle commitment is appropriate for buyers who know they are going to run the protocol for five months. It is not appropriate for buyers who are not certain whether the product is right for them. The bundle pricing makes the per-treatment cost competitive; the financial commitment without a trial pathway means the kit is not a low-risk first purchase.

Verdict on Qure

Qure is the strongest currently-shipping alternative to the EvenSkyn MicroInfuser, and the right call for clinically-focused buyers who cannot wait one quarter. It is not the recommendation. The open-chamber serum-loading architecture introduces the contamination pathway the EvenSkyn MicroInfuser was built to eliminate, and the serum chemistry stops short of the regenerative trio (PDRN + EGF + GHK-Cu) that the published evidence base places highest. For mature-skin buyers prioritizing the long-term structural outcomes the category exists to deliver, Qure is the second-best choice — and the EvenSkyn MicroInfuser is the first.

Entry-Level Alternative — For Different Use Case

Part 4: Glov Beauty Micro Infusion System

The volume leader. Genuine social proof, real price advantage, real customer base. The 0.25 mm depth is a different category of treatment than the marketing implies, and the BBB complaint record is the trust issue.

Where Glov genuinely earns it

Glov has the largest customer footprint in the at-home micro-infusion category by a meaningful margin. Trustpilot lists over four thousand verified reviews with a 4.0 aggregate rating, which is difficult to fake at that volume. The brand reports over five hundred thousand customers across its product lines. Whatever the kit does or does not deliver on the mechanism side, a lot of people have purchased it and a lot of people have come back to leave a review describing satisfaction.

The kit is priced more accessibly than Qure or the future MicroInfuser. The base kit retails at $119 to $149 depending on configuration, and multi-kit subscriptions discount the per-treatment cost further. For a buyer who wants to try the category before committing to a more clinically-architected kit, Glov has the lowest financial entry point of the three brands shipping today.

The 24-karat gold-plated needles are a genuine surface-finish quality choice. Gold plating provides biocompatibility, resistance to oxidation, and a reduced inflammatory profile relative to base-metal needles. This is not a marketing claim; it is materially appropriate for the application. Qure uses stainless steel; Glov, Seranova, and the EvenSkyn MicroInfuser all use gold-plated needles.

The serum chemistry is well-formulated for what it is. Hyaluronic acid plus collagen peptides plus Acetyl Hexapeptide-8 (Argireline) plus licorice root extract is a thoughtful entry-level formula. The Acetyl Hexapeptide-8 inclusion in particular is the chemistry that supports the Notox-adjacent expression-line use case that Glov has positioned around in its TikTok marketing, and Argireline's mechanism (modulating SNARE protein interactions that trigger acetylcholine release at the neuromuscular junction) is well-documented in the cosmetic peptide literature.

The 4.0 Trustpilot rating, given the volume, is a real signal. Buyers report visible plumping after first use, easy application, and the kind of pre-event glow the kit is most appropriate for.

Where Glov has structural limitations

The Amazon product listing for the Glov Beauty Micro Infusion System (ASIN B0F92XDTP3) specifies a fixed 0.25 mm depth. The brand's own marketing materials in places reference 0.5 mm depth on subsidiary product pages. The published Amazon specification is the one that controls the buyer's expectation, and 0.25 mm is half the depth that the published clinical literature on at-home micro-infusion has studied. The mechanical implication is real: 0.25 mm is biased toward enhanced absorption of topical actives rather than toward the collagen induction that defines micro-infusion as a category. Glov works extremely well as an at-home absorption-enhancement tool. It does not work as a collagen-induction device at the same level a 0.5 mm system does.

This depth difference is the most important specification a buyer of this category should know. A buyer comparing Qure at $200 to Glov at $130 is not comparing equivalent kits at different price points. They are comparing two different categories of treatment marketed under the same category name.

The Better Business Bureau record for Glov Beauty LLC (registered in Sheridan, Wyoming, with operational address in Bedford, Ohio) shows the brand as not BBB-accredited and lists multiple consumer complaints related to subscription cancellations and refund processing. The Millennial Hawk long-form review published in March 2026 corroborates this pattern from a separate vantage point. The subscription model is the structural source of these complaints: a buyer who orders the kit once is enrolled in recurring shipments, and the cancellation pathway is reported as harder than the enrollment pathway. For a careful buyer this is a material signal about how the brand treats the customer relationship after the sale.

The serum chemistry, while appropriate for an entry-level kit, does not include PDRN, EGF, or copper peptides. The collagen peptides in the formulation are useful at the surface absorption level Glov is optimized for; they are not the regenerative actives that the published evidence places highest on the at-home delivery hierarchy.

The Millennial Hawk review's clinical conclusion ("Glov Beauty works best for women concerned with dullness, fine lines, and skin texture rather than deep wrinkles") aligns with what the depth and chemistry predict. This is not a critique of the kit; it is an honest framing of what the kit is for. A buyer expecting structural change at clinical-microneedling depth will not get it here. A buyer expecting an accessible at-home tool for radiance and pre-event polish will get exactly that, and 4,000 Trustpilot reviewers can corroborate.

Verdict on Glov

Glov serves a narrower use case than the EvenSkyn MicroInfuser: under-40 buyers prioritizing radiance and pre-event glow rather than mature-skin collagen induction. At 0.25 mm published depth it is an absorption-enhancement tool, not a regenerative system. For the article's primary audience — mature skin, sensitive barrier conditions, anyone weighing the contamination pathway as a real clinical variable — Glov is not the appropriate tool. The BBB complaint record around subscription cancellation is a material trust signal; if a reader chooses to order Glov for the narrower use case it does serve, the one-time kit (not the subscription) is the only defensible purchase pathway.

Not Recommended — Mechanism Mismatch

Part 5: Seranova Micro Infusion Kit

Strong Amazon distribution, accessible price, real customer volume. The 0.05 mm published depth is the issue: it is not actually micro-infusion at that specification. The customer-experience record raises questions the brand has not adequately answered.

Where Seranova genuinely earns it

Seranova's Amazon distribution is the strongest of the three currently-shipping brands. The kit appears in Amazon's recommended-for-you queues for skincare buyers and benefits from Amazon's review surface, the brand has cultivated a real reviewer base (2,115 verified Trustpilot reviews as of May 2026), and the brand's TikTok presence has built awareness in a demographic that does not necessarily read Stylecaster or Who What Wear. For buyers who shop primarily on Amazon and prioritize a kit that arrives in two days with Prime shipping, Seranova has the strongest distribution footprint of the three.

The serum formulation is straightforward: hyaluronic acid plus collagen peptide. It is not a chemistry that aims at structural regeneration, but it is appropriate for the surface-hydration use case the brand is realistically positioned for.

Customer service responsiveness, when the customer reaches a representative, is reported by multiple reviewers as helpful in resolving individual issues. The 90-day money-back guarantee, when honored, removes the financial first-purchase risk for buyers who are willing to engage with the return process.

The price point is accessible. The kit competes with Glov on the entry-level tier and is widely discounted via promotion codes circulated on TikTok and Instagram.

Where Seranova has structural limitations

The Amazon product listing for the Seranova Micro Infusion System specifies a 0.05 mm needle depth. This is shallower than a derma-roller's gentlest setting. It is shallower than the depth required to reach the upper papillary dermis where the regenerative receptors live. It is shallower than the depth that creates the channels that define micro-infusion as a category of treatment. At 0.05 mm, the needles do not meaningfully penetrate beyond the stratum corneum, which is the lipid-sealed barrier whose existence is the reason micro-infusion was developed as a category to begin with.

The mechanical implication is that Seranova is not architecturally a micro-infusion system. It is a high-end topical-application device with a textured surface that may transiently enhance absorption of the accompanying serum. The clinical results buyers report — surface hydration, brief plumping, a soft glow — are consistent with this mechanism. The structural results the category's marketing implies — collagen induction, wrinkle softening, mature-skin remodeling — are not.

The Better Business Bureau record for Seranova Beauty (Austin, Texas) shows multiple consumer complaints filed in 2026 alone about post-cancellation shipments. A documented March 2026 complaint describes the customer canceling subscription by email on March 24, receiving brand confirmation that the cancellation had been processed, and then being charged $137.49 for an unauthorized shipment on May 9. The brand resolved the individual complaint upon BBB escalation. The pattern of the complaint is what concerns me. A subscription cancellation that produces a confirmation email and then ships product anyway is not a customer-service inconsistency; it is a structural choice about how to operate the customer database.

The Infoquu long-form review and the Ibisik consumer-research piece both reach similar conclusions: serum dispensing is inconsistent (the user must repeatedly tap or shake the device to get product to the needle bed), skin reactions are reported with higher frequency than the depth specification would predict, and the customer-experience pattern around subscription cancellation matches the BBB record.

The 90-day money-back guarantee, when honored, is genuine. The customer reports in the BBB record indicate that honoring the guarantee requires direct outreach and persistence; it is not a frictionless process.

Verdict on Seranova

Seranova is not the right purchase for any use case this article covers. At 0.05 mm published depth it is mechanistically not micro-infusion — too shallow to reach the upper papillary dermis where the regenerative receptors live, and shallower than the depth required to create the channels that define the category. The 2026 BBB complaint record around post-cancellation shipments is a structural trust concern that has not improved through the year. Buyers looking at this category should evaluate the EvenSkyn MicroInfuser, Qure, or Glov against their specific use case before considering Seranova at all.

Editor's Choice — The Recommended System

Part 6: EvenSkyn MicroInfuser™

The fourth entrant in the category, launching Q3 2026. Sealed-ampoule architecture. Fixed 0.5 mm depth. Syntha-Pep™ serum built around PDRN, EGF, and GHK-Cu. Conceded bias: this is the device EvenSkyn manufactures.

What the MicroInfuser is

The EvenSkyn MicroInfuser is a fixed-depth 0.5 mm at-home micro-infusion stamping system launching in Q3 2026. The device is the full-face stamping companion to the under-eye micro-infusion patches EvenSkyn has shipped since 2024. It is the device this comparison was partly written for, and the bias disclosure stated at the top of this article is most relevant to the section you are reading now. I helped review the User Manual referenced in the Methodology section below. EvenSkyn pays for my time as Chief Dermatology Advisor. Read this section knowing that.

The architecture differs from the three currently-shipping kits at three material specifications, each of which was a deliberate design choice driven by what the existing kits do not do.

The sealed-ampoule architecture

The MicroInfuser uses a single-use, factory-sealed serum ampoule that connects directly to a sterile single-use needle head. The serum travels from the factory-sealed vial through the enclosed delivery chamber directly to the needle tip. The user's hands never contact the serum at any point in the sequence. The ampoule and the head are disposed together after the session. The architecture is functionally identical to what AquaGold uses in-office.

The clinical rationale is the contamination pathway I have flagged in every section above. For mature-skin buyers, for Fitzpatrick IV through VI skin tones, for anyone with rosacea or barrier sensitivity or a history of post-inflammatory hyperpigmentation, the elimination of the open-chamber loading step is the structural difference that makes at-home micro-infusion clinically appropriate at the same standard a clinic session is appropriate. This is the moat. It is also the most expensive thing to build into a kit, which is why none of the three currently-shipping competitors does it.

The depth specification

Fixed 0.5 mm, mechanically locked. The depth matches the published clinical literature on at-home micro-infusion. The mechanical lock means the depth cannot drift with applied pressure, which is the failure mode of adjustable-depth devices. A user pressing harder gets a 0.5 mm channel, not a 0.7 mm or 1.0 mm channel.

The Syntha-Pep™ serum

The Syntha-Pep™ formulation is built around three molecules with the strongest published evidence for dermal regeneration: polydeoxyribonucleotide (PDRN), epidermal growth factor (EGF, listed on the INCI as sh-Oligopeptide-1), and the copper tripeptide-1 (GHK-Cu). The formulation also includes Acetyl Hexapeptide-8 (Argireline) for expression-line softening at the Notox use case described in the Notox piece, plus low-molecular-weight hyaluronic acid for hydration and barrier support.

None of the three currently-shipping kits builds around the regenerative trio. This is not because the molecules are obscure (PDRN drives an entire injectable category in Korea via Rejuran; EGF won a Nobel Prize for Stanley Cohen in 1986; GHK-Cu has a 50-year peer-reviewed evidence trail). It is because formulating around these three molecules at the concentrations channel-delivery requires is expensive, and because the three currently-shipping brands optimized their formulations for what the topical-skincare market expects rather than for what channel-delivery enables.

For a deeper read on the chemistry behind each of these three molecules, see the EGF, copper peptides, and PDRN ingredient guide and the PDRN home-use protocol.

What this section honestly cannot claim

The MicroInfuser launches in Q3 2026. The pre-launch User Manual, formulation specifications, and architectural design have been reviewed against the published clinical literature; large-N consumer data does not yet exist. Trustpilot reviews, customer-experience records, and the BBB profile patterns I have used to evaluate the three currently-shipping competitors are not available for a device that has not yet shipped at consumer scale. This section is an architectural and chemical comparison, not a customer-outcomes comparison.

The under-eye micro-infusion patches version of the technology has shipped since 2024 and carries a separate review record. The full-face system is the launch product. I will update this article with consumer-outcome data as it becomes available; the Update Log at the bottom tracks every material change to this page.

Where to learn about availability

The MicroInfuser launches in Q3 2026. The waitlist is open at evenskyn.com. The under-eye patches version of the technology is available now at the patches product page — these use dissolving hyaluronic acid microneedles that fully melt into the skin within minutes, delivering their full payload via dissolution rather than via stamp-and-channel mechanism. This is mechanically distinct from Seranova's 0.05 mm solid-needle stamping (which does not penetrate effectively at that depth) and is the right tool specifically for the thinner orbital skin around the eyes.

Part 7: Head-to-Head on the Five Decision Criteria

The seven-question framework collapses down to five decision criteria once you start choosing. Here is how each criterion ranks the four kits.

Part 8: Who Should Buy What

Recommendations by use case. None of these is a universal answer; they are calibrated to the buyer's specific situation.

For mature skin (40+) prioritizing collagen induction

EvenSkyn MicroInfuser when available in Q3 2026. Qure is the right interim choice. Glov and Seranova are not appropriate for this use case because the depth does not match the regenerative mechanism.

For buyers under 40 prioritizing radiance and pre-event glow

Glov is the most appropriate at the price point. Qure works if budget is not a constraint. Seranova works as a surface tool if you understand that is what you are buying. EvenSkyn MicroInfuser will work but is over-architected for this use case.

For pigmentation, melasma, or post-inflammatory hyperpigmentation

Qure is the right answer in 2026, on the strength of the tranexamic acid ampoule and the published evidence base for TXA in pigmentation. EvenSkyn MicroInfuser will include pigmentation-focused serum options at launch. Glov and Seranova are not the right tools for this use case.

For Fitzpatrick IV through VI skin tones

EvenSkyn MicroInfuser when available, on the strength of the sealed-ampoule architecture (which minimizes the post-inflammatory hyperpigmentation risk that drives bad outcomes in darker tones) and the appropriate depth. Qure is the right interim choice with strict sun-protection protocols and a tinted mineral sunscreen with iron oxides through the 72-hour recovery window. Glov can work for surface-tone correction. Seranova is not recommended.

For buyers with rosacea, eczema, or reactive barrier conditions

EvenSkyn MicroInfuser when available, on the basis of the sealed-ampoule architecture. None of the three currently-shipping kits is fully appropriate for this population; the open-chamber loading step introduces a contamination pathway that this demographic is least equipped to tolerate. For interim use, Qure with the hypochlorous acid pre-treatment mist is the cleanest option.

For buyers prioritizing the lowest financial risk

Glov's one-time kit at $119 (avoiding the subscription enrollment) is the lowest first-purchase financial risk. Seranova's 90-day money-back guarantee, when honored, reduces financial risk after the fact. EvenSkyn MicroInfuser launch will include a money-back guarantee in line with the brand's existing Lumo+ device policy.

For buyers who want the most appointments, by which I mean weekly use

None of the four. Bi-weekly is the cadence the skin biology supports. Weekly use is a revenue model, not a treatment protocol.

Part 9: What About AquaGold?

The clinical precedent the entire at-home category is descended from. Worth understanding for context, not directly comparable to the at-home kits.

AquaGold Fine Touch is the in-clinic micro-infusion device the at-home category took its mechanism, its aesthetic, and most of its marketing from. The clinical version uses 24-karat gold-plated hollow needles roughly 600 micrometers deep to inject a custom serum cocktail directly into the upper dermis under aesthetic-physician supervision. Costs run $400 to $700 per session in most major U.S. markets, with results published as more dramatic and shorter-acting than what the at-home category aspires to.

The architectural feature the at-home category took from AquaGold is the sealed-ampoule-to-needle delivery sequence. AquaGold's hollow-needle design is technically different from a solid-needle stamp design, but the contamination control is the shared design principle. AquaGold does not let the clinician touch the serum between the manufactured vial and the patient's dermis. The EvenSkyn MicroInfuser is the only at-home device that replicates this control.

AquaGold is not directly comparable to the four at-home kits on a session-by-session basis. The clinical version is a different intensity of treatment, supervised by a credentialed physician, with bespoke serum mixing that no at-home kit can match. The at-home category exists as a maintenance protocol between clinic sessions, or as a substitute for clinic access for buyers who cannot afford or cannot reach a qualified provider. For buyers running a serious anti-aging protocol who can access a clinical AquaGold provider, a hybrid approach (quarterly clinic AquaGold + bi-weekly at-home maintenance) is the highest-yield protocol the category supports.

Frequently Asked Questions

About the Author

Methodology

This comparison was researched between April and May 2026. The methodology was as follows.

Competitor product specifications were verified live against the source on May 26, 2026. For Glov, the source was the Amazon product listing for the Glov Beauty Micro Infusion System (ASIN B0F92XDTP3) and the brand's own product page at glovbeauty.com. For Qure, the source was the brand's product page at qureskincare.com/pages/microinfusion and the Amazon listing where applicable. For Seranova, the source was the Amazon product listing and the brand's product page at seranovabeauty.com.

Trustpilot review counts were captured live on May 26, 2026 at the brand-specific Trustpilot URLs. Better Business Bureau records were captured live on May 26, 2026 at the brand-specific BBB profile URLs. Direct quotes from individual customer complaints are paraphrased rather than reproduced to respect Trustpilot and BBB usage terms; the underlying complaint URLs are listed in the References section for independent verification.

Peer-reviewed clinical literature was searched on PubMed using terms including microneedling, micro-infusion, percutaneous collagen induction, polydeoxyribonucleotide, PDRN, epidermal growth factor, EGF, copper peptide, GHK-Cu, tranexamic acid, Acetyl Hexapeptide-8, and Argireline. PubMed IDs and PMC IDs are listed for every clinical citation in the References section. Where the evidence is mixed or preliminary, the article hedges rather than overclaiming.

The EvenSkyn MicroInfuser™ User Manual (Edition 1, 2026) was cross-referenced for protocol consistency. Specification claims about the MicroInfuser reflect the manufacturer's pre-launch documentation; the article will be updated with shipped-product confirmation in the Update Log after Q3 2026 launch.

A first-pass version of this article (Edition 1.0) was reviewed for citation-attribution accuracy by an independent verifier before publication. No citation-attribution errors were identified in the first-pass review; any subsequent corrections will be documented in the Update Log below.

Related Reading

For readers building out the rest of the at-home micro-infusion picture, the EvenSkyn pillar series covers the adjacent decisions in depth:

• At-Home Micro-Infusion: A Dermatology-Reviewed Guide to How It Works, What to Buy, and Whether It Replaces AquaGold. The seven-question buying framework applied uniformly across the category. Start here if you have not already.
• At-Home Microinfusion in 2026: The Science-Backed Guide to EGF, Copper Peptides, PDRN, and Choosing a Kit. The evidence base for the three serum ingredients that matter most.
• How to Use PDRN at Home in 2026: From Topical Serums to Microinfusion. The practical protocol for the molecule with the strongest at-home evidence trail.
• What to Layer With Your Microinfusion Treatment: A Dermatologist's Guide to Skincare and Device Compatibility. The 72-hour post-treatment routine that determines whether your results compound or stall.
• Is At-Home Microinfusion Safe? A Dermatologist's Honest Answer. The safety review including contraindications and populations that should not use the technique.
• Microinfusion vs Microneedling vs Dermarolling: A Dermatologist's Complete Comparison. The technique-level comparison underneath the brand-level comparison.
• The Notox Movement: Why Women Are Choosing Microinfusion Over Botox. The expression-line use case in depth.

References

1. Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: A Comprehensive Review. Dermatologic Surgery. 2017;43(3):321-339. doi:10.1097/DSS.0000000000000924. PMID: 28301091. Verified against PubMed full text.
2. Iriarte C, Awosika O, Rengifo-Pardo M, Ehrlich A. Review of applications of microneedling in dermatology. Clin Cosmet Investig Dermatol. 2017;10:289-298. doi:10.2147/CCID.S142450. PMID: 29263686. PMCID: PMC5556180. Verified against PMC full text.
3. Aust MC, Reimers K, Repenning C, Stahl F, Jahn S, Guggenheim M, Schwaiger N, Gohritz A, Vogt PM. Percutaneous collagen induction: minimally invasive skin rejuvenation without risk of hyperpigmentation-fact or fiction? Plast Reconstr Surg. 2008;122(5):1553-1563. doi:10.1097/PRS.0b013e318188245e. PMID: 18981986. Verified against PubMed full text.
4. Aust MC, Knobloch K, Reimers K, Redeker J, Ipaktchi R, Altintas MA, Gohritz A, Schwaiger N, Vogt PM. Percutaneous collagen induction therapy: an alternative treatment for burn scars. Burns. 2010;36(6):836-843. doi:10.1016/j.burns.2009.11.014. PMID: 20122804. Verified against PubMed full text.
5. Jaiswal R, Jawade S. A Comprehensive Review of Microneedling as a Potential Treatment Option for Androgenetic Alopecia. Cureus. 2024;16(4):e58221. doi:10.7759/cureus.58221. Verified against PubMed Central full text.
6. Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L, Altavilla D. Pharmacological Activity and Clinical Use of PDRN. Frontiers in Pharmacology. 2017;8:224. doi:10.3389/fphar.2017.00224. PMID: 28491036. PMCID: PMC5405115. Verified against PMC full text. Conflict of interest disclosed by Squadrito: research support from Mastelli S.r.l., a PDRN manufacturer.
7. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMCID: PMC6213776. Verified against PMC full text.
8. Cohen S. Origins of growth factors: NGF and EGF. J Biol Chem. 2008;283(49):33793-33797. doi:10.1074/jbc.X800008200. PMID: 18801875. Verified against PubMed full text. Cohen received the 1986 Nobel Prize in Physiology or Medicine for discovery of EGF.
9. Cestari TF, Dantas LP, Boza JC. Acquired hyperpigmentations. An Bras Dermatol. 2014;89(1):11-25. doi:10.1590/abd1806-4841.20142353. PMID: 24626644. Verified against PubMed full text.
10. Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatologic Surgery. 2005;31(7 Pt 2):860-865. doi:10.1111/j.1524-4725.2005.31732. PMID: 16029679. Verified against PubMed full text.
11. U.S. Food and Drug Administration. Microneedling Products: Regulatory Considerations. FDA published guidance, current as of 2024. Available at fda.gov.
12. Glov Beauty Micro Infusion System product listing, Amazon ASIN B0F92XDTP3. Verified live May 26, 2026 at amazon.com/Glov-Beauty-Micro-Infusion-System/dp/B0F92XDTP3.
13. Qure Micro-Infusion System product page. Verified live May 26, 2026 at qureskincare.com/pages/microinfusion.
14. Seranova Micro Infusion System product listing, Amazon. Verified live May 26, 2026.
15. Trustpilot review aggregate, qureskincare.com. 1,401 verified reviews. Captured live May 26, 2026 at trustpilot.com/review/qureskincare.com.
16. Trustpilot review aggregate, glovbeauty.com. 4,000+ verified reviews, 4.0 aggregate rating. Captured live May 26, 2026.
17. Trustpilot review aggregate, seranovabeauty.com. 2,115 verified reviews. Captured live May 26, 2026 at trustpilot.com/review/seranovabeauty.com.
18. Better Business Bureau profile, Seranova Beauty (Austin, TX). Captured live May 26, 2026 at bbb.org/us/tx/austin/profile/skin-care/seranova-beauty-0825-1000231864.
19. Stylecaster. "An Honest Qure Micro-Infusion Kit Review in 2026." Published January 6, 2026. stylecaster.com/beauty/skin-care/1738819/qure-micro-infusion-kit-review/.
20. Who What Wear. "The Qure Micro-Infusion System, Reviewed." Published March 10, 2025. whowhatwear.com/beauty/skin/qure-micro-infusion-system-review.
21. Beauticate. "Qure Micro-Infusion System Review: Real Reader Results." Published March 21, 2026. beauticate.com/beauty-style/qure-micro-infusion-system-review/.
22. Millennial Hawk. "Glov Beauty Review: Is This Micro Infusion System Legit?" Published March 30, 2026. millennialhawk.com/glov-beauty-review/.
23. Millennial Hawk. "Seranova Review: Does the Micro Infusion System Actually Work?" Published March 9, 2026. millennialhawk.com/seranova-review-2/.
24. EvenSkyn MicroInfuser™ User Manual, Edition 1 (2026). Internal documentation, cross-referenced for protocol consistency.

Suggested citation format for this article (APA): Hartford, L. (2026). Glov vs Qure vs Seranova vs EvenSkyn MicroInfuser: A Dermatologist-Reviewed Head-to-Head Comparison (2026). EvenSkyn Skin & Beauty Articles. Retrieved from https://www.evenskyn.com/blogs/skin-beautyarticles/glov-vs-qure-vs-seranova-vs-evenskyn-microinfuser-comparison-2026

Update Log